TRIB Stock Overview
Trinity Biotech plc adquiere, junto con sus filiales, desarrolla, fabrica y comercializa productos de diagnóstico médico para los segmentos de laboratorio clínico y punto de atención (POC) del mercado de diagnóstico en América, África, Asia y Europa.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Trinity Biotech plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.03 |
52 Week High | US$6.20 |
52 Week Low | US$1.85 |
Beta | 1.22 |
1 Month Change | -5.65% |
3 Month Change | -9.42% |
1 Year Change | -53.11% |
3 Year Change | -88.82% |
5 Year Change | -85.96% |
Change since IPO | -97.46% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%
Mar 02Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry
Dec 18A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)
Sep 12Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?
Aug 08Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price
Jun 09Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)
Apr 23This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts
Apr 23Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 01Trinity Biotech appoints former GE executive Aris Kekedjian as CEO
Oct 03At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?
Sep 01Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M
Jun 30Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)
Jun 14Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 23Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?
Feb 25Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability
Feb 02A Treatise On Trinity Biotech
Jan 13Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?
Jan 05What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?
Dec 10Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt
Nov 19Trinity Biotech EPS beats by $0.22, beats on revenue
Nov 17Shareholder Returns
TRIB | US Medical Equipment | US Market | |
---|---|---|---|
7D | 2.5% | -2.4% | -0.8% |
1Y | -53.1% | 7.6% | 26.6% |
Rentabilidad frente al sector: TRIB obtuvo unos resultados inferiores a los del sector US Medical Equipment , que el año pasado arrojó un rendimiento del 12.2%.
Rentabilidad vs. Mercado: TRIB obtuvo unos resultados inferiores a los del mercado US, que fue del 23.3% el año pasado.
Price Volatility
TRIB volatility | |
---|---|
TRIB Average Weekly Movement | 14.9% |
Medical Equipment Industry Average Movement | 7.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: TRIBha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: TRIB(17%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 398 | John Gillard | https://www.trinitybiotech.com |
Trinity Biotech plc adquiere, junto con sus filiales, desarrolla, fabrica y comercializa productos de diagnóstico médico para los segmentos de laboratorio clínico y punto de atención (POC) del mercado de diagnóstico en América, África, Asia y Europa. La empresa ofrece productos de laboratorio clínico, incluidas pruebas diagnósticas e instrumentación, que detectan enfermedades infecciosas, como la enfermedad de Lyme; enfermedades de transmisión sexual consistentes en sífilis y herpes; SARS-CoV-2; y epstein barr, sarampión, paperas, toxoplasmosis, citomegalovirus, rubéola, varicela y otros patógenos víricos, así como productos para las pruebas diagnósticas in vitro de hemoglobina A1c utilizadas en el seguimiento y diagnóstico de la diabetes, y la identificación de las personas con riesgo de desarrollar diabetes. También ofrece servicios de pruebas de laboratorio para el síndrome de Sjogren, la pérdida de audición, la enfermedad celíaca, el lupus, la artritis reumatoide, la esclerosis sistémica y otros servicios de pruebas de laboratorio para trastornos autoinmunes.
Trinity Biotech plc Fundamentals Summary
TRIB fundamental statistics | |
---|---|
Market cap | US$19.15m |
Earnings (TTM) | -US$39.20m |
Revenue (TTM) | US$71.39m |
0.3x
P/S Ratio-0.5x
P/E RatioIs TRIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TRIB income statement (TTM) | |
---|---|
Revenue | US$71.39m |
Cost of Revenue | US$46.35m |
Gross Profit | US$25.04m |
Other Expenses | US$64.24m |
Earnings | -US$39.20m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 04, 2024
Earnings per share (EPS) | -4.15 |
Gross Margin | 35.07% |
Net Profit Margin | -54.91% |
Debt/Equity Ratio | -311.6% |
How did TRIB perform over the long term?
See historical performance and comparison